[Form 8-K Current Report](index=1&type=section&id=Form%208-K%20Current%20Report) [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) Bruker Corporation announced unaudited preliminary Q2 2025 financial results, subject to change before final release on August 4 - The company issued a press release on **July 21, 2025**, announcing unaudited preliminary results for **Q2 2025**[5](index=5&type=chunk) - Preliminary financial results are subject to completion of financial closing procedures and could change significantly[6](index=6&type=chunk) - Bruker expects to announce final **Q2 financial results** before market open on **August 4, 2025**[6](index=6&type=chunk) [Forward-Looking Statements](index=2&type=section&id=Forward-Looking%20Statements) Forward-looking statements on preliminary Q2 2025 revenue and performance are subject to risks and uncertainties - Statements regarding preliminary **Q2 2025 revenue and performance** are considered forward-looking[8](index=8&type=chunk) - Forward-looking statements are subject to risks and uncertainties, with actual results potentially differing materially, as detailed in SEC filings[8](index=8&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01.%20Financial%20Statements%20and%20Exhibits.) This section lists Form 8-K exhibits, including the preliminary Q2 2025 results press release and interactive data Exhibit List | Exhibit Number | Description | | :--- | :--- | | 99.1 | Press release dated July 21, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

2018年，诺贝尔物理学奖授予了激光物理学领域的三位科学家。其中，时年96岁的阿瑟·阿什金 (Arthur Ashkin)凭借"光学镊子及其在生物系统中的应用"荣 膺该奖，成为史上最年长的诺贝尔物理学奖得主。 "光学镊子"（Optical Tweezers，OT）简称光镊，顾名思义就是用光做成的镊子。光是它的材质，镊是它的作用。虽然光镊的名字里带"镊"，但与传统镊 子需通过物理接触夹持物体不同，光镊是一种非机械接触式操控技术。其通过高度聚焦的激光束产生的力，像无形的镊子一样，精准操控细胞、病毒、 DNA等微小物体。 光镊的操控原理在于激光束产生的梯度力和散射力。梯度力如同磁铁吸引铁屑，将微小物体拉向光束中光强最强的中心区域；而散射力则像水流推动浮 萍，将物体沿着光束传播方向轻微推移。正是这两种力的精妙配合，使得光镊能够隔空"抓取"并移动目标对象。 光镊的突破启发了更多创新。2005年，美国加州伯克利大学吴明教授团队受光镊启发，将光控电场引入微粒操控领域发明了光电镊技术（OET），并于 2011年创立Berkeley Lights公司开始光电镊技术的产业化，2020年7月在美国纳斯达克上市，后被仪器巨头布鲁克（ ...

Core Viewpoint - The article discusses the advancements in animal hair identification in textiles using the MALDI-TOF mass spectrometry technology developed by Bruker, which addresses the challenges posed by traditional methods and enhances accuracy and reliability in detecting animal hair sources in textile products [1][2][12]. Group 1: Identification Challenges - Traditional methods for identifying animal hair in textiles, such as optical microscopy, are limited, especially when the samples undergo processing like bleaching or dyeing, which can damage DNA [1][2]. - Certain animal fibers, such as cashmere, sheep wool, and yak wool, have overlapping morphological characteristics, making it difficult to establish objective standards for identification [1]. Group 2: MALDI-TOF Technology Implementation - The Shanghai Customs Industrial Products and Raw Materials Testing Technology Center has established a national standard (GB/T 42699.2-2023) for the qualitative and quantitative analysis of animal hair fibers in textiles using MALDI-TOF-MS, which will be implemented in March 2024 [2]. - The MALDI-TOF-MS method allows for both accurate identification of animal hair sources and quantification of adulterated samples, demonstrating good reproducibility [2][11]. Group 3: Methodology and Results - The process involves extracting proteins from animal hair using SDS/DTT/phosphate buffer, purifying them through SDS-PAGE, and analyzing the resulting peptides with MALDI-TOF-MS to identify species based on characteristic peptide segments [3][4]. - Characteristic peptide segments for different animal species are concentrated in the mass-to-charge ratio range of 2450 m/z to 2750 m/z, allowing for precise identification [4][6]. Group 4: Performance and Reliability - The MALDI-TOF-MS method has shown excellent robustness with a relative standard deviation (RSD) of less than 5% over three years of testing different sample concentrations, ensuring data accuracy and reliability [11]. - The technology is not only applicable to textile analysis but can also be utilized in other fields, such as food adulteration detection [12].

Company Overview - Bruker Corporation (BRKR) has recently shipped and installed its 15th InSight WLI 3D optical metrology system for a leading semiconductor manufacturer, as part of a larger order for 27 systems in 2025 [1][8] - The InSight WLI system is designed for advanced packaging measurement requirements, providing non-contact, high-resolution 3D optical metrology essential for maintaining yield and quality in semiconductor manufacturing [6][8] Industry Context - The latest order highlights Bruker's integral role in the semiconductor industry's shift towards advanced packaging for AI chip manufacturing, which is crucial for meeting the demands of higher performance and energy efficiency in AI technologies [2][7] - The global advanced packaging market was valued at $38.50 billion in 2024 and is projected to grow at a compound annual growth rate of 11.5%, reaching $111.40 billion by 2034, driven by the increasing adoption of artificial intelligence [10] Financial Performance - Following the announcement of the new order, Bruker shares rose by 2.4%, closing at $39.66 [3] - Bruker has a market capitalization of $6.33 billion, with earnings expected to increase by 1.7% in 2025 according to the Zacks Consensus Estimate [5] Product Significance - Bruker's advanced metrology solutions are essential for addressing new manufacturing challenges introduced by advanced packaging, such as precision alignment and structural integrity, which are critical for AI workloads [7][8]

Summary of Bruker (BRKR) 2025 Conference Call Company Overview - **Company**: Bruker Corporation (BRKR) - **Event**: 2025 Conference Call held on June 04, 2025 Key Industry Insights - **Industry**: Mass Spectrometry and Proteomics - **Market Trends**: The mass spectrometry market is experiencing significant innovation, particularly in proteomics and metabolomics, with a focus on high sensitivity and throughput solutions [3][10][12] Core Product Innovations 1. **TIMS Ultra and AIP**: - New product launched to enhance MSMS sensitivity and bandwidth, allowing for more peptides and proteins to be analyzed [5][7] - Significant advancements in single-cell proteomics, enabling analysis of smaller cells than previously possible [8] 2. **TIMS Metabo Instrument**: - Aimed at the high-resolution accurate mass market for small molecules, targeting applications in PFAS research, toxicology, and metabolomics [11][12] - Expected to double the market opportunity for Bruker, potentially reaching a $200 million market share [15] 3. **TIMS Omni**: - A revolutionary mass spectrometer combining TIMS technology with Omni Trap, enabling top-down proteomics and functional proteomics [17][18] - Positioned to create a new category in mass spectrometry with no direct competition [19] Financial Outlook - **Revenue Guidance**: Anticipated moderate growth in 2026, with expectations of organic growth between 6% to 8% [32] - **Cost Management**: Bruker is implementing cost-cutting measures, including reducing operational costs in European sites and optimizing R&D spending [33][35] Market Dynamics - **Academic Market**: Anticipated decline in academic spending by 20-25% due to budget constraints, impacting overall revenue [22][30] - **Defense and Homeland Security**: Notable growth in the detection business for radiological and chemical threats, with potential revenue increases of $20 million next year [38][39] Emerging Markets and Opportunities - **Semiconductor and AI**: Strong demand in metrology for high-performance computing and AI applications, expected to grow from 8% to potentially 12% of total revenue [45][46] - **China Market**: Potential for stimulus-driven growth in high-end research tools, although timing remains uncertain [51][52] Strategic Developments - **Cell Analysis and Diagnostics**: Launch of a new benchtop product aimed at broadening market access for antibody discovery and cell line selection [54][55] - **Spatial Biology**: Continued investment in spatial biology technologies, enhancing capabilities in multi-omics and improving throughput and detection efficiency [61][62] Conclusion - Bruker is positioned for growth through innovative product offerings in mass spectrometry and proteomics, despite facing challenges in academic funding and market uncertainties. The company is strategically focusing on high-growth areas such as biopharma, diagnostics, and advanced manufacturing technologies.

Financial Data and Key Metrics Changes - The meeting confirmed that a quorum was present with over 95% of shares entitled to vote represented [3][4] - The compensation of $20.24 paid to named executive officers was approved by a non-binding advisory vote [10] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed in the meeting Market Data and Key Metrics Changes - No specific market data or key metrics were discussed in the meeting Company Strategy and Development Direction and Industry Competition - The company proposed the adoption of the 2026 Incentive Compensation Plan, indicating a focus on aligning executive compensation with long-term performance [7][10] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting Other Important Information - The appointment of PricewaterhouseCoopers as the independent registered public accounting firm for fiscal year 2025 was ratified [10] - Four Class I directors were elected to hold office until the 2028 Annual Meeting of Stockholders [10] Q&A Session All Questions and Answers - No questions were raised during the meeting, and the formal business concluded without further discussion [11][12]

Project Overview - The procurement project is for the purchase of field emission scanning electron microscopes and other scientific equipment for Zhengzhou University, with a total bid amount of 29.28 million [2][3]. - The project includes multiple packages, such as field emission scanning electron microscopes, mass spectrometers, and liquid chromatography mass spectrometry systems [3]. Procurement Details - The procurement method used was open bidding, with the announcement published on April 14, 2025, and the evaluation date set for May 7, 2025 [3]. - The delivery period is 180 calendar days from the effective date of the contract, and the delivery location is designated by the purchaser [3]. Bidder Information - The winning bids include: - HITACHI for a field emission scanning electron microscope at a price of 6,695,000 CNY [4]. - Bruker for a mass spectrometer at a price of 6,480,000 CNY [4]. - SCIEX for a liquid chromatography mass spectrometry system at a price of 4,990,000 CNY [5]. - Thermo Fisher Scientific for another liquid chromatography mass spectrometry system at a price of 8,220,000 CNY [5]. Quality Assurance - The quality assurance periods vary by package, with the field emission scanning electron microscope having a 5-year warranty and the mass spectrometers and liquid chromatography systems having a 3-year warranty [3].

Part I [Unaudited Condensed Consolidated Financial Statements](index=4&type=section&id=Item%201%3A%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) This section presents Bruker Corporation's unaudited financial statements for Q1 2025, including balance sheets, income statements, and cash flows, with notes on accounting policies and key events [Unaudited Condensed Consolidated Balance Sheets](index=4&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets increased to $5.93 billion from $5.81 billion at year-end 2024, driven by higher inventories and other assets, while total liabilities rose to $4.08 billion from $3.98 billion, primarily due to increases in deferred revenue and other current liabilities, and total shareholders' equity grew to $1.83 billion Condensed Consolidated Balance Sheet Data (in millions) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Total Assets** | **$5,933.1** | **$5,806.7** | | Total Current Assets | $2,111.5 | $2,053.2 | | Goodwill and intangible assets, net | $2,434.6 | $2,419.8 | | **Total Liabilities** | **$4,081.9** | **$3,991.5** | | Total Current Liabilities | $1,344.9 | $1,281.3 | | Long-term debt | $2,076.1 | $2,061.8 | | **Total Shareholders' Equity** | **$1,832.9** | **$1,797.1** | [Unaudited Condensed Consolidated Statements of Operations](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations) For the first quarter of 2025, total revenue increased by 11.0% year-over-year to $801.4 million, but operating income fell significantly to $31.8 million from $64.8 million in Q1 2024, largely due to higher operating expenses, resulting in net income attributable to Bruker Corporation decreasing to $17.4 million, or $0.11 per diluted share Q1 2025 vs. Q1 2024 Statement of Operations (in millions, except per share data) | Metric | Q1 2025 | Q1 2024 | Change (%) | | :--- | :--- | :--- | :--- | | Total Revenue | $801.4 | $721.7 | 11.0% | | Gross Profit | $391.2 | $352.8 | 10.9% | | Operating Income | $31.8 | $64.8 | (50.9)% | | Net Income Attributable to Bruker | $17.4 | $50.9 | (65.8)% | | Diluted EPS | $0.11 | $0.35 | (68.6)% | [Unaudited Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) In Q1 2025, net cash provided by operating activities significantly improved to $65.0 million from $21.8 million in Q1 2024, while net cash used in investing activities decreased sharply to $26.1 million from $304.2 million, and financing activities used $51.2 million in cash, a reversal from the $151.7 million provided in the prior-year quarter Cash Flow Summary (in millions) | Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $65.0 | $21.8 | | Net cash used in investing activities | $(26.1) | $(304.2) | | Net cash provided by (used in) financing activities | $(51.2) | $151.7 | | Net increase (decrease) in cash | $1.0 | $(148.3) | [Notes to Unaudited Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) This section details Bruker's business segments, acquisition updates, goodwill, legal contingencies, and a subsequent acquisition of RECIPE Chemicals + Instruments GmbH - The company operates through four reportable segments: BSI BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST)[21](index=21&type=chunk) - No acquisitions were completed in the first three months of 2025, with the report providing final valuation details for 2024 acquisitions of Chemspeed, and provisional details for NanoString and ELITechGroup[27](index=27&type=chunk)[34](index=34&type=chunk)[35](index=35&type=chunk) - Goodwill increased slightly to **$1.53 billion** as of March 31, 2025, primarily due to foreign currency effects[50](index=50&type=chunk) - The company is involved in significant patent litigation matters inherited from its acquisitions of PhenomeX (vs AbCellera) and NanoString (vs 10x Genomics), with the accrual for legal matters being **$96.4 million** as of March 31, 2025[98](index=98&type=chunk)[100](index=100&type=chunk)[101](index=101&type=chunk) - Subsequent to the quarter end, on April 14, 2025, the company acquired a **69.6% stake** in RECIPE Chemicals + Instruments GmbH for approximately **$65.3 million**[112](index=112&type=chunk) [Management's Discussion and Analysis (MD&A)](index=30&type=section&id=Item%202%3A%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q1 2025 revenue growth and operating income decline due to acquisition and litigation costs, highlighting improved operating cash flow and liquidity [Results of Operations](index=33&type=section&id=Results%20of%20Operations) Revenue for Q1 2025 grew 11.0% to $801.4 million, with BSI CALID and BSI BioSpin segments showing strong growth largely due to 2024 acquisitions, but operating income fell to $31.8 million from $64.8 million YoY, pressured by increased SG&A, R&D, and a significant jump in 'Other charges, net' Revenue by Segment (in millions) | Segment | Q1 2025 Revenue | Q1 2024 Revenue | % Change | | :--- | :--- | :--- | :--- | | BSI BioSpin | $207.8 | $182.8 | 13.7% | | BSI CALID | $280.1 | $227.9 | 22.9% | | BSI NANO | $256.6 | $240.4 | 6.7% | | BEST | $59.3 | $73.1 | (18.9)% | | **Total** | **$801.4** | **$721.7** | **11.0%** | - The increase in 'Other charges, net' to **$36.9 million** was primarily due to **$18.6 million** of acquisition-related litigation charges (related to BCA and NanoString), **$7.6 million** in restructuring charges, and **$2.1 million** in other acquisition-related expenses[141](index=141&type=chunk) - The effective tax rate increased to **34.7%** from **27.7%** in the prior year, mainly due to changes in jurisdictional mix and the impact of Pillar 2 global minimum tax rules, which added **2.1%** to the rate[146](index=146&type=chunk)[147](index=147&type=chunk) [Liquidity and Capital Resources](index=36&type=section&id=Liquidity%20and%20Capital%20Resources) The company anticipates existing cash and credit facilities are sufficient for the next twelve months, with net cash from operations at $65.0 million, total debt at $2.1 billion, and access to a $900.0 million revolving credit facility, while repurchasing $10.0 million of common stock during the quarter - The company believes existing cash and credit facilities are sufficient to support operating and investing needs for at least the next twelve months[148](index=148&type=chunk) Key Cash Flow Data (in millions) | Cash Flow Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $65.0 | $21.8 | | Net cash used in investing activities | $(26.1) | $(304.2) | | Net cash provided by (used in) financing activities | $(51.2) | $151.7 | - During Q1 2025, the company repurchased **200,731 shares** for **$10.0 million** under its share repurchase program, with no shares repurchased in Q1 2024[154](index=154&type=chunk) - As of March 31, 2025, the company had total outstanding debt of **$2.1 billion** and a revolving credit facility providing up to **$900.0 million** in backup liquidity[155](index=155&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=38&type=section&id=Item%203%3A%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) There were no material changes in the company's exposure to market risk from December 31, 2024, except for newly identified tariff risks, as a new universal 10% baseline tariff on all U.S. imports, announced on April 2, 2025, is expected to increase the company's cost of goods sold - A new universal baseline tariff of **10%** on all U.S. imports, announced on April 2, 2025, is expected to increase the company's costs of goods sold[159](index=159&type=chunk) [Controls and Procedures](index=38&type=section&id=Item%204%3A%20Controls%20and%20Procedures) Management, including the CEO and CFO, evaluated the company's disclosure controls and procedures and concluded they were effective as of March 31, 2025, with no material changes in internal control over financial reporting during the quarter - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of March 31, 2025[160](index=160&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[162](index=162&type=chunk) Part II [Legal Proceedings](index=39&type=section&id=Item%201%3A%20Legal%20Proceedings) The company is involved in various legal proceedings arising in the ordinary course of business, with material pending legal matters disclosed in Note 20 of the financial statements, detailing significant patent litigation, and is also subject to governmental investigations from time to time - Other than matters disclosed in Note 20 (Commitments and Contingencies), the company is not party to any material pending legal proceedings outside the ordinary course of business[163](index=163&type=chunk) [Risk Factors](index=39&type=section&id=Item%201A%3A%20Risk%20Factors) There have been no material changes to the risk factors previously disclosed in the company's Annual Report on Form 10-K for the year ended December 31, 2024 - The report refers to the risk factors discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, indicating no material changes[165](index=165&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=39&type=section&id=Item%202%3A%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During the first quarter of 2025, the company repurchased 200,731 shares of its common stock at an average price of $49.81 per share, for a total cost of approximately $10.0 million, with approximately $359.9 million remaining available for future repurchases under the authorized program as of March 31, 2025 Share Repurchase Activity for Q1 2025 | Period | Total Shares Purchased | Average Price Paid | Total Cost (approx.) | | :--- | :--- | :--- | :--- | | Jan 2025 | 0 | $— | $0 | | Feb 2025 | 200,731 | $49.81 | $10.0M | | Mar 2025 | 0 | $— | $0 | | **Total Q1** | **200,731** | **$49.81** | **$10.0M** | - As of the end of the quarter, **$359.9 million** remained available for repurchase under the 2023 Repurchase Program, which authorizes up to **$500.0 million** in buybacks over a two-year period[167](index=167&type=chunk)[168](index=168&type=chunk) [Other Information](index=40&type=section&id=Item%205%3A%20Other%20Information) On February 18, 2025, Dr. Cynthia Friend, a member of the Board of Directors, adopted a Rule 10b5-1 trading plan for the potential sale of company shares underlying her equity awards, set to terminate by December 15, 2025, or when all shares under the plan are sold - On February 18, 2025, Director Dr. Cynthia Friend adopted a Rule 10b5-1 trading plan to sell up to **5,192 shares** from vested RSUs and **4,300 shares** from stock options[169](index=169&type=chunk) [Exhibits](index=41&type=section&id=Item%206%3A%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including CEO and CFO certifications as required by the Sarbanes-Oxley Act (Sections 302 and 906) and the Inline XBRL financial data files - Exhibits filed include CEO/CFO certifications (31.1, 31.2, 32.1) and Inline XBRL documents (101 series)[171](index=171&type=chunk)

Bruker (BRKR) Q1 2025 Earnings Call May 07, 2025 08:30 AM ET Company Participants Joe Kostka - Director, Head of Investor RelationsFrank Laukien - Chairman, CEO & PresidentGerald Herman - Executive VP & CFOPuneet Souda - Senior MDMichael Ryskin - Managing DirectorPatrick Donnelly - Managing DirectorTycho Peterson - Managing Director, Global EquitiesLuke Sergott - Director - Healthcare Equity ResearchSubbu Nambi - Managing DirectorDoug Schenkel - Managing Director Conference Call Participants Rachel Vatnsdal ...

Bruker (BRKR) Q1 2025 Earnings Call May 07, 2025 08:30 AM ET Speaker0 Good day, and welcome to the Bruker Corporation First Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Joe Director of Investor Relations. Please go ahead. Speaker1 Good morning. I would like to welcome everyone to Bruker Corpo ...